Stockreport

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study [Yahoo! Finance]

Lexeo Therapeutics, Inc.  (LXEO) 
PDF Clinically meaningful improvements in majority of participants across cardiac biomarkers and functional measures All SUNRISE-FA participants achieved meaningful incre [Read more]